TITLE

Drivers and barriers to acceptance of human-papillomavirus vaccination among young women: a qualitative and quantitative study

AUTHOR(S)
Mortensen, Gitte Lee
PUB. DATE
January 2010
SOURCE
BMC Public Health;2010, Vol. 10 Issue 1, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Human papillomavirus (HPV) is a necessary cause of cervical dysplasia and cancer, and of genital warts. Few studies have examined attitudes to HPV vaccination since the introduction of HPV vaccines. We aimed to investigate the reasons for young women's acceptance or rejection of the quadrivalent HPV vaccine after its general availability in Denmark. Method: A literature review assessed attitudes towards HPV vaccination and the information was used to identify relevant questions for telephone and focus group interviews with women aged 16-26 who had decided to receive or reject HPV vaccination. 435 women across Denmark were interviewed by telephone. Qualitative interviews were undertaken in focus groups with 33 women living in Odense who had completed the telephone survey. Four focus groups were set up according to age (16-20 and 21-26 years of age) and acceptance/rejection of the vaccine. Results: Of 839 women initially contacted by telephone, 794 were included, 411 (49%) said they accepted vaccination but only 201 (24%) had actually received the vaccine and these latter were interviewed. 242 women said they refused vaccination of which 234 were interviewed. Women who were undecided were excluded from the study. Prevention of cervical cancer was the main driver for acceptance of the vaccine, followed by parental encouragement and financial support, personal experience of someone with cancer and recommendation by health-care professionals. The greatest barrier to vaccination was its cost. A lack of information about the benefits of vaccination for sexually active women was also an important barrier and the older participants in particular considered that they were too old to be vaccinated. Knowledge about HPV and its role in the development of cervical cancer and genital warts was poor. Conclusions: The difference between intention to be vaccinated and starting vaccination was considerable, and a large proportion of women aged 16-26 did not wish to be vaccinated. If the most important barriers to vaccination were addressed (cost and a lack of information about vaccination benefits), it is likely that the uptake of vaccination in Denmark would increase substantially.
ACCESSION #
48497351

 

Related Articles

  • HPV linked to other types of genital cancer.  // CMAJ: Canadian Medical Association Journal;11/15/97, Vol. 157 Issue 10, p1340 

    Examines the fact that human papillomaviruses (HPVs) that cause genital warts are known to cause cervical cancer. The research in Finland linking some HPV infections with other types of genital cancer; The tests of various HPV strains.

  • Initial trials examine HPV wart therapies. Guttman, Cheryl // Dermatology Times;Sep98, Vol. 19 Issue 9, p3 

    Focuses on clinical trials that may lead to treatment for patients with cutaneous or genital warts caused by human papillomavirus (HPV). Information about the phases of the clinical trials; How the PEN203 antiviral agent was designed; Effectiveness offered by interferon in treating genital...

  • GARDASIL: WHAT YOU NEED TO KNOW ABOUT THE HPV Vaccine.  // Network Magazine of the Canadian Women's Health Network;Spring/Summer2007, Vol. 9 Issue 3/4, p14 

    The article offers information about the Gardasil, a human papillomavirus (HPV) vaccine approved for use in Canada and the U.S. It is noted that this specific vaccine prevents infection from HPV types 6 and 11, which cause genital warts, and HPV types 16 and 18, which cause cancer. However, the...

  • 3. Successful Management of Viral Infections and Other Dermatoses with Imiquimod 5% Cream. Berman, Brian; Hengge, Ulrich; Barton, Simon // Acta Dermato-Venereologica;Sep2003 Supplement 214, Vol. 83, p12 

    The immune response modifier imiquimod 5% cream is a safe, effective and established treatment for external genital and perianal warts. Human papillomavirus (HPV) is the most common sexually transmitted infection in many countries. Current recommended treatment options for genital warts are...

  • Evaluation of urine as a potential alternative sample for the diagnosis of Human Papillomavirus (HPV) related cervical lesions: A pilot study. Hassan, Rania Ahmed; El Sayed, Shereen Bendary; Helmy, Mouchira Fayek; Shehab El Din, Zeinab Abdel Kader; El-Shourbagy, Mahmoud Ali // Nature & Science;Jun2012, Vol. 10 Issue 6, p38 

    Background: Despite the high prevalence of both human papillomavirus (HPV) infections and cervical cancer, the ability to test for HPV infection of the uterine cervix is limited by a lack of an easy sample collection method that does not require gynecological examination. This study was done to...

  • Prevalence and Determinants of High-Risk Human Papillomavirus Infection in Male Genital Warts. Sung Jin Park; Juhyung Seo; Seong-Heon Ha; Gyung-Woo Jung // Korean Journal of Urology;Mar2014, Vol. 55 Issue 3, p207 

    Purpose: To evaluate the prevalence and type distribution of high-risk human papillomavirus (HPV) infection in genital warts of Korean men, and for the first time, to describe the risk factors associated with high-risk HPV infection in male genital warts. Materials and Methods: In a single...

  • An overview of genital warts. Richards, Sara // Nursing Standard;2/12/2014, Vol. 28 Issue 24, p46 

    Genital warts are a common sexually transmitted infection that is particularly prevalent in young people. Although the warts are usually painless and rarely cause any long-term health problems, they can cause significant psychological distress and relationship problems for those affected. This...

  • Monitoring the coverage and impact of human papillomavirus vaccine -- report of WHO meeting, November 2009.  // Weekly Epidemiological Record;6/18/2010, Vol. 85 Issue 25, p237 

    The article reports on the coverage and impact monitoring of the human pappilomavirus vaccine (HPV). It states that monitoring vaccine coverage of HPV is valuable in the evaluation of vaccine programs and vaccine impact. It also cites several possible biological resultants for the monitoring...

  • HPV vaccine and its recommendations, 2007. Zimmerman, Richard Kent // Journal of Family Practice;Feb2007 Supplement, Vol. 56 Issue 2, pS1 

    Quadrivalent human papillomavirus vaccine against the viral types most likely to cause cervical cancer (types 16 and 18) and genital warts (types 6 and 11) has been licensed in the United States. The vaccine is 95% to 100% efficacious against cervical intraepithelial neoplasia and adenocarcinoma...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics